MOTS-c and 5-Amino-1MQ Together: What Is Known
MOTS-c and 5-Amino-1MQ taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 10 of 12 fields where the two differ. Category, Half-life are the same or both unknown.
| Field | MOTS-c | 5-Amino-1MQ |
|---|---|---|
| Class | Mitochondrial-derived peptide | NNMT inhibitor (not a peptide) |
| Also called | mots | 5-amino, 1MQ |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | PCAC voted 7–5 for 503A (Jul 2026) | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. | WADA status unclear5-Amino-1MQ is not named. S4.4 covers AMPK activators, PPAR-delta agonists and Rev-erb agonists by example, and nothing there names an NNMT inhibitor. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 | Animal evidence, 2 of 4Strongest: Scientific reports 2022, PMID 35013352 |
| Human studies we summarised | 7 human (4 randomized or controlled) of 15 summarised | 0 human (0 randomized or controlled) of 4 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg, 20 mg, 40 mg | 5 mg, 10 mg |
MOTS-c vs 5-Amino-1MQ
Choosing between the two rather than combining them? The comparison lines them up field by field.
What each has shown, and in what species
MOTS-c prevented age-dependent and diet-induced insulin resistance and diet-induced obesity in mice.[20]
5-amino-1MQ with a low-fat diet drove whole-body adiposity and weight down in diet-induced obese mice.[12]
Enzyme and diabetes-model findings
The structure work on 5-amino-1MQ screened N-methylated quinolinium analogues and identified quinoliniums as a promising scaffold for NNMT inhibition.[21]
MOTS-c ameliorated the development of hyperglycemia in autoimmune-diabetic mice.[22]
Combined and regulated
The MOTS-c plus 5-amino-1MQ search came back with 0 records.
Calculated from pubmed query ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("MOTS-c"[tiab] OR MOTSc[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key 5-amino-1mq__mots-c); no arithmetic applied.
In the cached WADA list, MOTS-c is named in the clause on AMPK activators.[2]
5-amino-1MQ has no FDA-approved product.[23]
Common questions
MOTS-c vs 5-amino-1MQ: which has more research?
MOTS-c has a larger evidence file, mostly mouse work, than 5-amino-1MQ, whose studies are mouse, enzyme and cell work.
Calculated from mots cstudies 15; five amino1mq studies 4. Formula: Length of the studies array in web/src/data/evidence/mots-c.json (15) and 5-amino-1mq.json (4); no other arithmetic.
Is there a MOTS-c and 5-amino-1MQ blend study?
No study of the two together exists in the cached search; both datasets are preclinical.[12]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 4Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 5Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 6Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 7PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
- 13Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
- 14PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("MOTS-c"[tiab] OR MOTSc[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 18PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 20The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Cell metabolism · 2015PMID 25738459Accessed 2 Oct 2026
- 21Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.Journal of medicinal chemistry · 2017PMID 28548833Accessed 2 Oct 2026
- 22Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes.Cell reports · 2021PMID 34320351Accessed 2 Oct 2026
- 23Drugs@FDA (openFDA) search: active ingredient "5-amino-1MQ"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.